Zelanna Goldberg

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors

Mark G. Kris, D. Ross Camidge, Giuseppe Giaccone et al. · Annals of Oncology · 2015 · 332 citations · Full text

Medicine, Oncology, Pharmacology +17

Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial

Suresh S. Ramalingam, Pasi A. Jänne, Tony Mok et al. · The Lancet Oncology · 2014 · 138 citations

Medicine, Oncology, Pharmacology +9

Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial

Frances A. Shepherd, Michael Millward, Lesley Seymour et al. · The Lancet Oncology · 2014 · 128 citations

Medicine, Oncology, Pharmacology +10

Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial

Pasi A. Jänne, Sai‐Hong Ignatius Ou, Dong‐Wan Kim et al. · The Lancet Oncology · 2014 · 124 citations

Medicine, Oncology, Pharmacology +8

Phase II Study of Tirapazamine, Cisplatin, and Etoposide and Concurrent Thoracic Radiotherapy for Limited-Stage Small-Cell Lung Cancer: SWOG 0222

Quynh‐Thu Le, James Moon, Mary W. Redman et al. · Journal of Clinical Oncology · 2009 · 60 citations · Full text

Medicine, Oncology, Pharmacotherapy +13